Safety with ocrelizumab in rheumatoid arthritis: Results from the ocrelizumab phase III program

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Emery, Paul ^a,b   Rigby, William ^c   Tak, Paul P ^d,h   Dor̈ner, Thomas ^e   Olech, Ewa ^f   Martin, Carmen ^g   Millar, Laurie ^g   Travers, Helen ^g   Fisheleva, Elena ^g  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^g ROCHE PRODUCTS LTD   (United Kingdom)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; METHOTREXATE; OCRELIZUMAB; PLACEBO; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVERSE DRUG REACTION; ANAPHYLAXIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; B LYMPHOCYTE; CANCER INCIDENCE; CANDIDIASIS; CELLULITIS; CHILL; DIZZINESS; DOSE RESPONSE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; ESOPHAGUS CANDIDIASIS; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS B; HISTOPLASMOSIS; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; INFUSION RELATED REACTION; LEUKOENCEPHALOPATHY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RIGOR; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROAT IRRITATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA; VIRUS PNEUMONIA; WEAKNESS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; META ANALYSIS (TOPIC); MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEOPLASM; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFECTION; MALE; META-ANALYSIS AS TOPIC; METHOTREXATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84896832227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087379     Document Type: Article

References (14)

1. Dörner T, Kinnman N, Tak PP (2010) Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 125: 464-475.
2. Silverman GJ, Carson DA (2003) Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 5: S1-6. (Pubitemid 38239909)
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806. (Pubitemid 44497758)
4. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581. (Pubitemid 38758544)
5. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390-1400.
6. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, et al. (2010) Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biologic naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69: 1629-1635.
7. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, et al. (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 49: 1683-1693.
8. van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, et al. (2010) Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37: 558-567.
9. van Vollenhoven RF, Emery P, Bingham CO III, Keystone E, Fleischmann R, et al. (2012) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients. Ann Rheum Dis [Epub ahead of print].
10. Rigby W, Tony HP, Oelke K, Combe B, Laster A, et al. (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64: 350-359.
11. Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, et al. (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64: 360-370.
12. Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, et al. (2012) Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial. Ann Rheum Dis 71: 1289-1296.
13. Huffstutter JE, Taylor J, Schechtman J, Leszczynski P, Brzosko M, et al. (2011) Single versus dual infusion of B cell depleting antibody ocrelizumab (humanized aCD20) in rheumatoid arthritis: Results from the Phase III FEATURE trial. Int J Clin Rheumatol 6: 689-696.
14. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, et al. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779-1787.